Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,062 recruiting studies in this area right now.
By phase
- Not applicable3,004
- Phase 21,058
- Phase 1794
- Phase 1/Phase 2439
- Phase 3436
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis329
- Multiple Myeloma328
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis131
- Type 1 Diabetes131
- Atopic Dermatitis124
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California497
- Maryland199
- Alabama177
- Florida152
- Arizona148
- Massachusetts117
- New York116
- Texas112
- Colorado82
- Illinois82
Recruiting studies6,062 total
- NCT07312188RecruitingPhase 2
F182112 for relapsed or refractory multiple myeloma
This trial tests a new drug, F182112, for people whose multiple myeloma came back or didn't respond to prior treatments that included lenalidomide and a proteasome inhibitor. It may help if your disease has active signs like high protein levels.
TianjinAges 18 years+ - NCT07312630RecruitingEarly Phase 1
A study of LV009 for certain blood cancers
This trial tests an experimental treatment called LV009 for people with certain types of blood cancers that have come back or not responded to previous treatments. The treatment targets a protein called CD19 found on cancer cells.
Hefei, AnhuiAges 18–70 - NCT07309055RecruitingPhase 3
Study of SHR-1819 injection for teens with severe eczema
This trial tests an injectable medicine called SHR-1819 for teenagers aged 12 to 17 with severe atopic dermatitis (eczema) that has not responded well to creams or other treatments. The goal is to see if it can improve skin symptoms and reduce itching.
Shenyang, LiaoningAges 12–17 - NCT06799611RecruitingPhase 2
CM336 for immune thrombocytopenia (ITP)
This trial tests a new drug called CM336 for people with immune thrombocytopenia (ITP) that hasn't responded well to other treatments. It aims to see if CM336 can safely help raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07309848Recruiting
Hip fracture surgery timing and blood transfusion risk on DOACs
This study looks at whether the timing of hip fracture surgery affects the need for blood transfusions in patients taking blood thinners (DOACs). It might help guide better care for people on these medications.
AlmeloAges Any age - NCT07312045Recruiting
Gum health and healing after non-surgical treatment
This study looks at how certain blood and saliva measurements relate to gum disease and healing after a deep cleaning. It may help find better ways to track gum health.
Merkez, ErzincanAges 18–65 - NCT07312266Recruiting
Questioning asymptomatic TB in HIV patients
This study looks for tuberculosis (TB) in people with HIV who have no symptoms. It aims to understand how common hidden TB is, which could lead to better detection and prevention.
Manhiça, Maputo ProvinceAges 18 years+ - NCT07309614RecruitingPhase 3
Dupilumab for asthma remission
This trial tests whether dupilumab, a medicine that helps reduce airway inflammation, can help people with asthma achieve remission. You may be eligible if you have asthma with high markers of inflammation and have had asthma attacks despite using your regular inhaler.
Nedlands, Western AustraliaAges 18–79 - NCT07313462Recruiting
Comparing treatment strategies for MS starting after age 50
This trial looks at two ways to treat multiple sclerosis (MS) that begins after age 50. It compares starting with a stronger medication right away versus starting with a milder one and then switching if needed.
StrasbourgAges 50 years+ - NCT07312474Recruiting
Study of Anaplasmosis Cases in Alsace
This study looks at people in Alsace, France, who have been diagnosed with anaplasmosis (a tick-borne infection). It aims to understand the disease's patterns and symptoms.
StrasbourgAges 18 years+ - NCT07311746RecruitingPhase 1/Phase 2
Study of cladribine, ruxolitinib, and venetoclax for T-PLL
This trial tests a combination of three drugs (cladribine, ruxolitinib, and venetoclax) for people with T-cell prolymphocytic leukemia (T-PLL) that has come back or stopped responding to prior treatment. The goal is to see if this therapy can help control the disease.
Houston, TexasAges 18 years+ - NCT07309497Recruiting
Geriatric Assessment for Older Adults Before CAR-T or Bispecific Therapy
This trial studies how a simple geriatric assessment (a check-up for older adults) can help predict side effects and outcomes in patients aged 65+ who are about to receive CAR-T cell therapy or bispecific antibody treatment.
BernAges 65 years+ - NCT07315191RecruitingPhase 4
Finerenone for IgA vasculitis with mild proteinuria in children
This trial tests if the drug finerenone can help children with IgA vasculitis (HSP nephritis) who have mild protein in their urine. It aims to protect kidney function without using stronger medications like steroids.
Beijing, Beijing MunicipalityAges 3–18 - NCT07314892Recruiting
Psychiatric health and symptom severity in GvHD patients
This study looks at how graft-versus-host disease (a complication after a bone marrow transplant) affects mental health and symptom severity. It aims to understand the connection so that doctors can better support patients.
Gdansk, Pomeranian VoivodeshipAges 18–75 - NCT07313943Recruiting
Study of PAX5-negative Hodgkin-like lymphomas
This study looks at a rare type of lymphoma that looks like Hodgkin lymphoma but lacks a protein called PAX5. The goal is to better understand and diagnose this condition, which can be hard to tell apart from other lymphomas.
TübingenAges 18 years+ - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT07313982Recruiting
Leukemia study looking at LEF1 protein levels
This study is examining levels of a protein called LEF1 in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Researchers want to see if LEF1 can help predict survival and confirm diagnosis.
Bologna, BOLOGNAAges 18 years+ - NCT07312942Recruiting
Breathing and exercise for multiple myeloma patients
This trial tests whether adding slow, controlled breathing exercises to a supervised exercise program can improve your quality of life and physical function while you are on daratumumab treatment for multiple myeloma.
MadridAges 18 years+ - NCT06793956RecruitingPhase 1
Testing sintilimab and linperlisib for NK/T-cell lymphoma
This trial tests a combination of two drugs, sintilimab (immunotherapy) and linperlisib (targeted therapy), for people whose NK/T-cell lymphoma has come back or did not respond to previous treatment. The goal is to see if this combination can help shrink or control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06874608Recruiting
Does an exclusion diet help juvenile arthritis?
This study tests if removing certain foods can improve arthritis symptoms in children aged 6 to 17. It may be an option if current medicines are not working well or if you want to explore dietary changes.
FlorenceAges 6–18 - NCT04867915Recruiting
Study of CLL, SLL, and related blood conditions in Italy
This is a study that looks back and forward at people diagnosed with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or a related early condition called MBL. It aims to improve how these conditions are recognized and managed over time in Italy.
AlessandriaAges 18 years+ - NCT06028087Recruiting
Blood Clot Prevention Study in Myeloma Patients
This study looks at how blood thinners are used in people with newly diagnosed multiple myeloma. The goal is to find better ways to prevent blood clots during treatment.
RomaAges 18 years+ - NCT07301255RecruitingPhase 2
ENV-294 for moderate-to-severe asthma in adults
This trial tests an experimental drug called ENV-294 in adults with moderate-to-severe asthma. You may join if you are already using two kinds of inhalers regularly and have had at least one asthma flare-up in the past year that needed steroids or a hospital visit.
Birmingham, AlabamaAges 18–75 - NCT07299422RecruitingPhase 2
Study of SHR-2173 for people with lupus
This trial tests a new drug called SHR-2173 for people with active lupus. It aims to see if it can reduce disease activity when taken with standard treatments.
Beijing, Beijing MunicipalityAges 18–65
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,062 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,151 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.